The Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA) for Aubagio (teriflunomide; Genzyme) that includes revisions to the Contraindications, Warnings and ...
Osteoarthritis affects 600 million people worldwide, making it a leading cause of disability. With no disease-modifying treatments available or on the horizon, oral non-steroidal anti-inflammatory ...
MYRBETRIQ (mirabegron) 25mg and 50mg extended-release tablets by Astellas The Food and Drug Administration (FDA) has approved changes to the Myrbetriq (mirabegron; Astellas Pharma) label to include a ...
People who are newly diagnosed with knee or hip osteoarthritis continue to take non-steroidal anti-inflammatory drugs (NSAIDs) despite contraindications, a new study shows. A team from Boston ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results